Axon Enterprise (AXON) News Today

Axon Enterprise (NASDAQ:AXON) Hits New 12-Month High at $378.89

Harel Insurance Investments & Financial Services Ltd. lifted its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 492.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,018 shares of the biot

Sumitomo Mitsui Trust Holdings Inc. cut its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 8.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 155,398 shares of the biotechnology company's stoc

Vaughan Nelson Investment Management L.P. lifted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 53.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,094 shares of the biotechnology com

Swedbank AB raised its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 2.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 130,397 shares of the biotechnology company's stock after acquiring an additional 2,800 shares during the p

Axon Enterprise (NASDAQ:AXON) Reaches New 1-Year High at $378.25

Diversified Trust Co boosted its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 85.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,969 shares of the biotechnology company's stock after buying an additional 1,829 s

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares in the company, valued at $1,783,916.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Northland Securities lifted their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an "outperform" rating in a research report on Thursday.

AMF Tjanstepension AB raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 23.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,402 shares of the biotechnology company

Axon Enterprise (NASDAQ:AXON - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business's revenue for the quarter was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.80 EPS.

Barclays boosted their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an "overweight" rating in a report on Wednesday.

Axon Enterprise (NASDAQ:AXON) Sets New 1-Year High Following Earnings Beat

Cetera Investment Advisers grew its holdings in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 280.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,067 shares of the biotechnology company's stock after

Cetera Advisors LLC boosted its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 49.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,623 shares of the biotechnology company's stock after purchasing an additional 2,532 shares d

DekaBank Deutsche Girozentrale grew its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 45.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 16,986 shares of the biotechnology company's stock after buying an additional 5,301 shares during the quar

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the

Swedbank AB acquired a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund acquired 127,597 shares of the biotechnology company's stock, valued at approximately $39,923,000. Swedbank AB owned approximately 0